Alcon Inc is a global leader in the eye care industry, specializing in the development and manufacturing of innovative products aimed at enhancing vision and eye health
The company offers a comprehensive range of surgical and vision care solutions, including advanced intraocular lenses, surgical instruments, contact lenses, and eye care products. With a commitment to improving patient outcomes and quality of life, Alcon employs cutting-edge technology and research to address various eye conditions and promote healthier vision for individuals around the world.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity®, the most widely implanted9 extended depth of focus (EDOF) intraocular lens (IOL), is now available on Alcon’s most advanced lens material—Clareon®.1 Clareon Vivity® received CE Mark and will commence commercial rollout in Europe from early Q2 2025.
Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract surgery.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond laser-assisted cataract surgery (FLACS) offering.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –2.75D cylinder offering.
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.57 and core diluted earnings per share2 of $0.72 in the fourth quarter of 2024.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE® PRO Preservative-Free (PF) as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE portfolio with a unique triple action, preservative-free formula for the temporary relief of burning and irritation due to dryness of the eye.1
Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager™ DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment’s availability for more patients. Designed for an exceptional patient and physician experience, Voyager DSLT is fully automated—efficiently delivering 120 laser pulses without the need for a gonio lens as with manual SLT.2,3 Attendees of the 2025 American Glaucoma Society (AGS) meeting in Washington, D.C., from February 26 through March 2, will be able to experience Voyager DSLT first-hand at the Alcon booth (#29-32) and during the launch event (registration is available: here).
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.53 and core diluted earnings per share2 of $0.81 in the third quarter of 2024.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7®, the only one-week replacement contact lens with the revolutionary 7-day ACTIV-FLO® System2 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase its latest clinical data and product innovations at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. Ophthalmologists, surgical staff, researchers, and industry leaders can visit Alcon at booth #4008 for hands-on demonstrations and engaging experiences.
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.45 and core diluted earnings per share2 of $0.74 in the second quarter of 2024.
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to $1.5 billion in milestones plus royalties.
